Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Comment] Digoxin use in atrial fibrillation: a critical reappraisal

Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia, affecting more than 33·5 million individuals worldwide.1 Despite pharmacological advances in the past two centuries, digoxin remains the oldest and one of the most common adjunctive treatments for rate control in AF. Although reports show a persistent decrease in overall digoxin prescription rates,2 its use remains common in contemporary AF trials in nearly a third of participants.3